THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin's lymphoma in elderly patients: a prospective study.

Abstract	THP-COPBLM including pirarubicin (THP), which is thought to be less toxic than doxorubicin, was used to treat non-Hodgkin's lymphoma (NHL) and the remission rate and adverse effects were studied in 26 patients older than 70 years. Complete remission (CR) was achieved in 19 patients (73.1%) and partial remission in three (11.5%). Classified by stages, CR was achieved in seven out of nine stage II patients and 12 out of 17 stage III, IV patients. The 2-year survival rate was 60.3%. Grade 3 or higher adverse effects included leukopenia in eight patients (30.8%), anemia in three (11.5%), thrombocytopenia in two (7.7%) and nausea/vomiting in 1 (3.8%). The THP-COPBLM regimen appears useful for the treatment of NHL in elderly patients. The regimen was seldom associated with gastrointestinal symptoms and cardiotoxicity. Despite the administration of granulocyte colony-stimulating factor (G-CSF), however, the white blood cell count decreased in many patients, suggesting the necessity for further study of this regimen to modify the dose of THP.
Authors	N Niitsu, M Umeda
Journal	Leukemia (Leukemia) Vol. 11 Issue 11 Pg. 1817-20 (Nov 1997) ISSN: 0887-6924 [Print] England
PMID	9369412 (Publication Type: Journal Article)
Chemical References	Bleomycin Granulocyte Colony-Stimulating Factor Procarbazine Vincristine Doxorubicin Cyclophosphamide pirarubicin Prednisone
Topics	Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use) Bleomycin (administration & dosage) Cyclophosphamide (administration & dosage) Doxorubicin (administration & dosage, analogs & derivatives) Female Granulocyte Colony-Stimulating Factor (administration & dosage, adverse effects, therapeutic use) Humans Lymphoma, Non-Hodgkin (drug therapy, mortality) Male Prednisone (administration & dosage) Procarbazine (administration & dosage) Prospective Studies Survival Analysis Treatment Outcome Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!